Literature DB >> 12596090

Current management of acute bronchiolitis in Switzerland.

J Barben1, J Hammer.   

Abstract

INTRODUCTION: Acute bronchiolitis is the most common lower respiratory tract infection in the first year of life. Current expert opinion and scientific data suggest that pharmaceutical agents have little impact on the natural course of the disease.
METHODS: Postal questionnaires were sent to all Swiss paediatricians to assess their current practice for treating acute bronchiolitis in children.
RESULTS: Of a total of 937 questionnaires, 541 (58%) were returned. Of the respondents, 422 (78%) treat children with acute bronchiolitis. Up to 99% of paediatricians used bronchodilators in the outpatient and inpatient management, either routinely (up to 62%) or occasionally (37%). Steroids were used by 41% of the respondents in outpatient management and by 57% in inpatient management. The paediatric respiratory physicians tended to use bronchodilators and corticosteroids less frequently than the general paediatricians.
CONCLUSIONS: A wide variation in the treatment of bronchiolitis was noted. Despite lack of evidence of benefit most Swiss paediatricians use pharmaceutical agents in the management of acute bronchiolitis. In particular, bronchodilators and corticosteroids were used in inpatient management in Switzerland much more frequently than recently reported for Australian paediatricians. National guidelines could be helpful in reducing the variations in the management of acute bronchiolitis in our country.

Entities:  

Mesh:

Year:  2003        PMID: 12596090     DOI: 2003/01/smw-10093

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  8 in total

1.  Virologic testing in bronchiolitis: does it change management decisions and predict outcomes?

Authors:  Fabiola Stollar; Gabriel Alcoba; Alain Gervaix; Constance Barazzone Argiroffo
Journal:  Eur J Pediatr       Date:  2014-05-25       Impact factor: 3.183

2.  Management of acute bronchiolitis in emergency wards in Spain: variability and appropriateness analysis (aBREVIADo Project).

Authors:  Carlos Ochoa Sangrador; Javier González de Dios
Journal:  Eur J Pediatr       Date:  2012-02-21       Impact factor: 3.183

Review 3.  Bronchodilators for bronchiolitis.

Authors:  Anne M Gadomski; Melissa B Scribani
Journal:  Cochrane Database Syst Rev       Date:  2014-06-17

Review 4.  Glucocorticoids for acute viral bronchiolitis in infants and young children.

Authors:  Ricardo M Fernandes; Liza M Bialy; Ben Vandermeer; Lisa Tjosvold; Amy C Plint; Hema Patel; David W Johnson; Terry P Klassen; Lisa Hartling
Journal:  Cochrane Database Syst Rev       Date:  2013-06-04

5.  Risk factors for bronchiolitis severity: A retrospective review of patients admitted to the university hospital from central region of Slovenia.

Authors:  Ajda Praznik; Neža Vinšek; Ana Prodan; Vanja Erčulj; Marko Pokorn; Tatjana Mrvič; Darja Paro; Uroš Krivec; Franc Strle; Miroslav Petrovec; Marta Žnidaršič Eržen; Štefan Grosek
Journal:  Influenza Other Respir Viruses       Date:  2018-08-09       Impact factor: 4.380

6.  Frequency, Timing, Risk Factors, and Outcomes of Desaturation in Infants With Acute Bronchiolitis and Initially Normal Oxygen Saturation.

Authors:  Fabiola Stollar; Alban Glangetas; Fanny Luterbacher; Alain Gervaix; Constance Barazzone-Argiroffo; Annick Galetto-Lacour
Journal:  JAMA Netw Open       Date:  2020-12-01

7.  The effect of high dose inhaled corticosteroids on wheeze in infants after respiratory syncytial virus infection: randomised double blind placebo controlled trial.

Authors:  Marieke J J Ermers; Maroeska M Rovers; Job B van Woensel; Jan L L Kimpen; Louis J Bont
Journal:  BMJ       Date:  2009-03-31

8.  Safely Discharging Infants with Bronchiolitis from an Emergency Department: A Five Step Guide for Pediatricians.

Authors:  Fabiola Stollar; Alain Gervaix; Constance Barazzone Argiroffo
Journal:  PLoS One       Date:  2016-09-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.